Green Thumb Industries (GTBIF) Net Income towards Common Stockholders (2019 - 2026)
Green Thumb Industries (GTBIF) reported Net Income towards Common Stockholders of $15.0 million for Q1 2026, up 79.11% on a YoY basis from $8.4 million in Q1 2025, and down 85.22% quarter-over-quarter from $101.8 million in Q4 2025.
Green Thumb Industries (GTBIF) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Green Thumb Industries has reported Net Income towards Common Stockholders for 8 years, with the latest figure at $15.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 79.11% year-over-year to $15.0 million; the trailing twelve-month figure through Mar 2026 stood at $141.4 million (up 215.29% YoY), and the FY2025 full-year result was $134.8 million, up 98.78% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $15.0 million, down from $101.8 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $101.8 million in Q4 2025, with the low at -$50.9 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged $15.8 million across 5 years, with a median of $10.8 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 311.7% — and 2025, when it soared 1407.83%.
- Green Thumb Industries' Net Income towards Common Stockholders stood at -$50.9 million in 2022, then surged by 106.91% to $3.5 million in 2023, then jumped by 92.04% to $6.8 million in 2024, then soared by 1407.83% to $101.8 million in 2025, then plunged by 85.22% to $15.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $15.0 million (Q1 2026), $101.8 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Green Thumb Industries | - | - | 143.65 Mn | 15.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.05 Mn |
| Dec 31, 2025 | 101.84 Mn |
| Sep 30, 2025 | 23.80 Mn |
| Jun 30, 2025 | 732,000.00 |
| Mar 31, 2025 | 8.40 Mn |
| Dec 31, 2024 | 6.75 Mn |
| Sep 30, 2024 | 8.78 Mn |
| Jun 30, 2024 | 20.92 Mn |
| Mar 31, 2024 | 31.35 Mn |
| Dec 31, 2023 | 3.52 Mn |
| Sep 30, 2023 | 10.81 Mn |
| Jun 30, 2023 | 13.69 Mn |
| Mar 31, 2023 | 9.41 Mn |
| Dec 31, 2022 | -50.91 Mn |
| Sep 30, 2022 | 10.15 Mn |
| Jun 30, 2022 | 24.73 Mn |
| Mar 31, 2022 | 29.69 Mn |
| Dec 31, 2021 | 24.05 Mn |
| Sep 30, 2021 | 21.59 Mn |
| Jun 30, 2021 | 23.27 Mn |